ClinicalTrials.gg
TerminatedNCT00818259Updated Sep 25, 2018Results posted

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)

A Phase 1 interventional study of Experimental: aprepitant and Experimental: fosaprepitant in Chemotherapy-Induced Nausea and Vomiting, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2018-09-25.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Why this study was terminated
Study terminated early prior to completing targeted enrollment of participants \<6 months of age due to recruitment challenges.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Non-randomized
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 61 studies testing aprepitant in Vomiting — 3 open to participants now, 3 under way, 1 of them phase 3. Aprepitant · Vomiting.

Enrollment
31st of 61
92 · median 92
Started
2009
with 5 others
Phase 1
6 of 61
none open now
Registered
17th of 61
by date
Lead sponsor
9 of 61
Merck Sharp & Dohme LLC

Among the 61 studies testing aprepitant in Vomiting, this one is the 31st largest by enrollment, is one of 6 that started in 2009, is one of 6 in phase 1, and was the 17th registered.

Vomiting

794 studies on the registry are indexed under Vomiting; 99 are open to participants now.

Browse Vomiting studies →

Open to participants now

3 of the 61 studies testing aprepitant in Vomiting are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About aprepitant

Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Vomiting studies recruiting now, 26 (46%) set no upper age limit and 24 (43%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing aprepitant in Vomiting, or all of them as a file.
02

Study summary

This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0 months to 17 years of age.

Read the detailed description

Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after intravenous administration; the pharmacological effect of fosaprepitant is attributed to aprepitant. The birth to one year old cohort will be initiated in Parts III and IV upon completion of Part II (Steps A and B) in participants \<6 months of age.

03

Conditions studied

  • Chemotherapy-Induced Nausea and Vomiting

Browse trials for

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is 0 (at least 37 weeks gestation) to 17 years of age
  • Is scheduled to receive moderately to highly nausea-inducing chemotherapy or participant did not tolerate a previous chemotherapy regimen that is planned to be repeated
  • Is expected to receive ondansetron
  • Female participants who have begun menstruating must have a negative pregnancy test
  • Weighs ≥3.0 kg if \<6 months of age, ≥6.0 kg if >6 months of age, and ≥7.5 kg if > 2 years of age
  • Has a pre-existing venous catheter

Exclusion criteria

Exclusion Criteria:

  • Uses any illicit drugs or abuses alcohol
  • Is pregnant or breast feeding
  • Has a symptomatic central nervous system (CNS) tumor
  • Has an infection or other uncontrolled disease other than cancer
  • Has known history of heart wave prolongation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Part IA-fosaprepitant 115 mg/aprepitant

    Day 1, fosaprepitant intravenous (IV) at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg orally (PO), prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.

    Drug: Experimental: aprepitant · Drug: Experimental: fosaprepitant · Drug: Ondansetron · Drug: Dexamethasone

  • Experimental
    Part IB-fosaprepitant 150 mg

    Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.

    Drug: Experimental: fosaprepitant · Drug: Ondansetron · Drug: Dexamethasone

  • Experimental
    Part IIA-aprepitant 80 mg equiv.

    Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to \<12 years of age - 47 mg/m\^2; 4 months to \<6 months of age - 2.0 mg/kg; 1 month to \<4 months of age - 1.0 mg/kg; birth to \<1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.

    Drug: Experimental: aprepitant · Drug: Ondansetron · Drug: Dexamethasone

  • Experimental
    Part IIB-aprepitant 125 mg equiv.

    Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to \<12 years of age - 74 mg/m\^2; 6 months to \<2 years of age - 1.3 mg/kg; 4 months to \<6 months of age - 3.0 mg/kg; 1 month to \<4 months of age - 1.5 mg/kg; birth to \<1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.

    Drug: Experimental: aprepitant · Drug: Ondansetron · Drug: Dexamethasone

  • Active comparator
    Part III-ondansetron

    Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to \<12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.

    Drug: Comparator: ondansetron · Drug: Dexamethasone

  • Experimental
    Part IV-aprepitant regimen

    Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to \<12 years of age - 3.0 mg/kg; 1 month to \<4 months of age - 1.5 mg/kg; Birth to \<1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to \<12 years of age - 2.0 mg/kg; 1 month to \<4 months of age - 1.0 mg/kg; Birth to \<1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.

    Drug: Experimental: aprepitant · Drug: Ondansetron · Drug: Dexamethasone

  • Experimental
    Part V-fosaprepitant regimen

    Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to \<12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.

    Drug: Experimental: fosaprepitant · Drug: Ondansetron · Drug: Dexamethasone

Interventions

  • aprepitant powder for suspension, 125 mg/sachet, PO

    Also known as: Emend, MK-0869

  • fosaprepitant lyophilized powder for suspension, 115 mg/vial or 150 mg/vial, IV

    Also known as: Emend injection, Fosaprepitant Dimeglumine, MK-0517

  • ondansetron solution for infusion, IV, administered per local standard of care

    Also known as: Zofran

  • ondansetron solution for infusion, IV, administered per local standard of care

  • dexamethasone solution for infusion, IV, administered per local standard of care

06

What researchers measure

Primary outcomes

  1. Area Under the Time-Concentration Curve From 0 to 24 Hours (AUC 0-24hr) for Aprepitant

    AUC is a measure of the amount of aprepitant in the plasma. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for pharmacokinetic (PK) assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hours (hr) post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8 and 24 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy.

    Time frame: Up to 24 hours post fosaprepitant/aprepitant dose

  2. Maximum Plasma Concentration (Cmax) for Aprepitant

    Cmax is a measure of the maximum amount of aprepitant in the plasma. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.

    Time frame: Up to 72 hours post fosaprepitant/aprepitant dose

  3. Time to Cmax (Tmax) for Aprepitant

    Tmax is a measure of the amount of time after dosing to when the maximum concentration of aprepitant was achieved. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.

    Time frame: Up to 72 hours post fosaprepitant/aprepitant dose

  4. Apparent Terminal Half-life (t1/2) for Aprepitant

    t1/2 is the amount of time from dosing until half of the aprepitant was metabolized from the body. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.

    Time frame: Up to 72 hours post fosaprepitant/aprepitant dose

  5. Cmax for Fosaprepitant

    Cmax is a measure of the maximum amount of fosaprepitant in the plasma. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.

    Time frame: Up to 72 hours post fosaprepitant dose

  6. Tmax for Fosaprepitant

    Tmax is a measure of the amount of time after dosing to when the maximum concentration of fosaprepitant was achieved. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.

    Time frame: Up to 72 hours post fosaprepitant dose

  7. Number of Participants Experiencing Adverse Events (AEs)

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Participants were monitored for the occurrence AEs for up to 14 days after last dose of study drug.

    Time frame: Up to 14 days after last dose of study drug (Up to 17 days)

  8. Number of Participants Discontinuing Study Drug Due to an AE

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. The number of participants who discontinued from the study due to an AE are summarized.

    Time frame: Day 1 up to Day 3

Secondary outcomes

  1. Plasma Concentration and PK Parameters of Dexamethasone in Participants From Birth to 1 Year of Age

    Blood samples for PK assessment were to be collected at the following time points: Parts II and V - Pre-dose and 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy; Parts III and IV - Immediately after infusion of dexamethsone and 0.5, 1.5, 3, 8 and 24 hr post start of chemotherapy.

    Time frame: Up to 24 hours post dexamethasone dose

07

Results

Posted Nov 18, 2014

Participant flow

Randomization
Participant flow — Randomization
MilestonePart IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart IV-Additional EnrollersPart V-fosaprepitant RegimenPart V-Additional Enrollers
Started12111920190506
Completed12111920190506
Not completed000000000
Part I
Participant flow — Part I
MilestonePart IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart IV-Additional EnrollersPart V-fosaprepitant RegimenPart V-Additional Enrollers
Started12110000000
Completed11110000000
Not completed100000000
Withdrew: Withdrawal by subject100000000
Part II
Participant flow — Part II
MilestonePart IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart IV-Additional EnrollersPart V-fosaprepitant RegimenPart V-Additional Enrollers
Started00192000000
Treated00191900000
Completed00181800000
Not completed001200000
Withdrew: Physician decision001000000
Withdrew: Lack of efficacy000100000
Withdrew: Not treated000100000
Part III
Participant flow — Part III
MilestonePart IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart IV-Additional EnrollersPart V-fosaprepitant RegimenPart V-Additional Enrollers
Started0000190000
Completed0000190000
Not completed000000000
Part IV
Participant flow — Part IV
MilestonePart IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart IV-Additional EnrollersPart V-fosaprepitant RegimenPart V-Additional Enrollers
Started0000015500
Completed0000014500
Not completed000001000
Withdrew: Physician decision000001000
Part V
Participant flow — Part V
MilestonePart IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart IV-Additional EnrollersPart V-fosaprepitant RegimenPart V-Additional Enrollers
Started0000000176
Completed0000000166
Not completed000000010
Withdrew: Adverse event000000010

Outcome measures

PrimaryArea Under the Time-Concentration Curve From 0 to 24 Hours (AUC 0-24hr) for Aprepitant

AUC is a measure of the amount of aprepitant in the plasma. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for pharmacokinetic (PK) assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hours (hr) post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8 and 24 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy.

Time frame:
Up to 24 hours post fosaprepitant/aprepitant dose
Reported as:
Mean · hr*ng/mL
Area Under the Time-Concentration Curve From 0 to 24 Hours (AUC 0-24hr) for Aprepitant
hr*ng/mLPart IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart V-fosaprepitant Regimen
6 months to <2 years (n=0, 0, 5, 5, 0, 6, 6)NA ± NANA ± NA20000 ± 78906310 ± 2040—21100 ± 1180011700 ± 6980
2 years to <6 years (n=0, 0, 8, 7, 0, 6, 7)NA ± NANA ± NA16400 ± 808023000 ± 8390—17300 ± 506018300 ± 11100
6 years to <12 years (n=0, 0, 6, 6, 0, 6, 8)NA ± NANA ± NA16000 ± 481022000 ± 9440—24400 ± 1580019500 ± 6720
12 years to 17 years (n=8, 11, 0, 0, 0, 0, 0)19500 ± 801030800 ± 7020NA ± NANA ± NA—NA ± NANA ± NA
PrimaryMaximum Plasma Concentration (Cmax) for Aprepitant

Cmax is a measure of the maximum amount of aprepitant in the plasma. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.

Time frame:
Up to 72 hours post fosaprepitant/aprepitant dose
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) for Aprepitant
ng/mLPart IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart V-fosaprepitant Regimen
6 months to <2 years (n=0, 0, 5, 5, 0, 6, 7)NA ± NANA ± NA1930 ± 1000659 ± 107—1810 ± 9251700 ± 636
2 years to <6 years (n=0, 0, 8, 7, 0, 6, 7)NA ± NANA ± NA1300 ± 6092100 ± 1170—1840 ± 9332430 ± 1100
6 years to <12 years (n=0, 0, 6, 6, 0, 7, 8)NA ± NANA ± NA1300 ± 2751930 ± 873—1800 ± 16102850 ± 641
12 years to 17 years (n=12, 11, 0, 0, 0, 0, 0)3240 ± 12805870 ± 2770NA ± NANA ± NA—NA ± NANA ± NA
PrimaryTime to Cmax (Tmax) for Aprepitant

Tmax is a measure of the amount of time after dosing to when the maximum concentration of aprepitant was achieved. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.

Time frame:
Up to 72 hours post fosaprepitant/aprepitant dose
Reported as:
Mean · hr
Time to Cmax (Tmax) for Aprepitant
hrPart IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart V-fosaprepitant Regimen
6 months to <2 years (n=0, 0, 5, 5, 0, 6, 7)NA ± NANA ± NA2.33 ± 1.163.45 ± 2.89—7.34 ± 8.281.13 ± 0.17
2 years to <6 years (n=0, 0, 8, 7, 0, 6, 7)NA ± NANA ± NA3.78 ± 1.925.28 ± 1.97—4.92 ± 2.201.41 ± 0.83
6 years to <12 years (n=0, 0, 6, 6, 0, 7, 8)NA ± NANA ± NA5.17 ± 1.833.08 ± 0.95—6.42 ± 7.841.07 ± 0.11
12 years to 17 years (n=12, 11, 0, 0, 0, 0, 0)0.41 ± 0.270.64 ± 0.30NA ± NANA ± NA—NA ± NANA ± NA
PrimaryApparent Terminal Half-life (t1/2) for Aprepitant

t1/2 is the amount of time from dosing until half of the aprepitant was metabolized from the body. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.

Time frame:
Up to 72 hours post fosaprepitant/aprepitant dose
Reported as:
Mean · hr
Apparent Terminal Half-life (t1/2) for Aprepitant
hrPart IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart V-fosaprepitant Regimen
6 months to <2 years (n=0, 0, 5, 3, 0, 3, 6)NA ± NANA ± NA7.28 ± 1.478.09 ± 2.54—6.18 ± 4.127.71 ± 3.10
2 years to <6 years (n=0, 0, 6, 4, 0, 5, 7)NA ± NANA ± NA8.27 ± 2.676.06 ± 3.03—9.21 ± 5.576.44 ± 2.35
6 years to <12 years (n=0, 0, 5, 6, 0, 4, 8)NA ± NANA ± NA9.17 ± 4.006.89 ± 1.35—10.8 ± 4.278.76 ± 3.34
12 years to 17 years (n=6 11, 0, 0, 0, 0, 0)11.0 ± 4.4222.2 ± 19.8NA ± NANA ± NA—NA ± NANA ± NA
PrimaryCmax for Fosaprepitant

Cmax is a measure of the maximum amount of fosaprepitant in the plasma. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.

Time frame:
Up to 72 hours post fosaprepitant dose
Reported as:
Mean · ng/mL
Cmax for Fosaprepitant
ng/mLPart IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart V-fosaprepitant Regimen
6 months to <2 years (n=0, 0, 0, 0, 0, 0, 7)—NA ± NA————2756 ± 3364
2 years to <6 years (n=0, 0, 0, 0, 0, 0, 8)—NA ± NA————3034 ± 1718
6 years to <12 years (n=0, 0, 0, 0, 0, 0, 8)—NA ± NA————1654 ± 1995
12 years to 17 years (n=0, 11, 0, 0, 0, 0, 0)—1310 ± 964————NA ± NA
PrimaryTmax for Fosaprepitant

Tmax is a measure of the amount of time after dosing to when the maximum concentration of fosaprepitant was achieved. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.

Time frame:
Up to 72 hours post fosaprepitant dose
Reported as:
Mean · hr
Tmax for Fosaprepitant
hrPart IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart V-fosaprepitant Regimen
6 months to <2 years (n=0, 0, 0, 0, 0, 0, 7)—NA ± NA————1.13 ± 0.175
2 years to <6 years (n=0, 0, 0, 0, 0, 0, 7)—NA ± NA————1.05 ± 0.089
6 years to <12 years (n=0, 0, 0, 0, 0, 0, 8)—NA ± NA————1.04 ± 0.088
12 years to 17 years (n=0, 11, 0, 0, 0, 0, 0)—0.614 ± 0.251————NA ± NA
PrimaryNumber of Participants Experiencing Adverse Events (AEs)

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Participants were monitored for the occurrence AEs for up to 14 days after last dose of study drug.

Time frame:
Up to 14 days after last dose of study drug (Up to 17 days)
Reported as:
Number · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsPart IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart V-fosaprepitant Regimen
Number of Participants Experiencing Adverse Events (AEs)1161816151317
SecondaryPlasma Concentration and PK Parameters of Dexamethasone in Participants From Birth to 1 Year of Age

Blood samples for PK assessment were to be collected at the following time points: Parts II and V - Pre-dose and 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy; Parts III and IV - Immediately after infusion of dexamethsone and 0.5, 1.5, 3, 8 and 24 hr post start of chemotherapy.

Time frame:
Up to 24 hours post dexamethasone dose

No measurements were reported for this outcome.

PrimaryNumber of Participants Discontinuing Study Drug Due to an AE

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. The number of participants who discontinued from the study due to an AE are summarized.

Time frame:
Day 1 up to Day 3
Reported as:
Number · Participants
Number of Participants Discontinuing Study Drug Due to an AE
ParticipantsPart IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart V-fosaprepitant Regimen
Number of Participants Discontinuing Study Drug Due to an AE0000001

Adverse events

Collected over Up to 14 days after last dose of study drug (Up to 17 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part IA-fosaprepitant 115 mg/Aprepitant—4/12 (33.3%)11/12 (91.7%)
Part IB-fosaprepitant 150 mg—1/11 (9.1%)5/11 (45.5%)
Part IIA-aprepitant 80 mg Equiv.—7/19 (36.8%)18/19 (94.7%)
Part IIB-aprepitant 125 mg Equiv.—4/19 (21.1%)15/19 (78.9%)
Part III-ondansetron—5/19 (26.3%)15/19 (78.9%)
Part IV-aprepitant Regimen—2/20 (10%)13/20 (65%)
Part V-fosaprepitant Regimen—9/23 (39.1%)16/23 (69.6%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPart IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart V-fosaprepitant Regimen
Febrile neutropeniaBlood and lymphatic system disorders2/120/114/192/194/192/204/23
NeutropeniaBlood and lymphatic system disorders1/120/112/191/190/190/202/23
VomitingGastrointestinal disorders0/120/112/190/190/190/200/23
Enterobacter bacteraemiaInfections and infestations0/121/110/190/190/190/200/23
ThrombocytopeniaBlood and lymphatic system disorders1/120/110/191/190/190/200/23
Septic shockInfections and infestations1/120/110/190/190/190/200/23
LymphopeniaBlood and lymphatic system disorders0/120/110/191/190/190/200/23
DiarrhoeaGastrointestinal disorders0/120/111/190/190/190/200/23
EnteritisGastrointestinal disorders0/120/110/190/191/190/200/23
NauseaGastrointestinal disorders0/120/111/190/190/190/200/23
Most frequent other events
Showing 10 of 107
Most frequent other events
EventPart IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart V-fosaprepitant Regimen
VomitingGastrointestinal disorders5/120/119/198/192/191/205/23
NauseaGastrointestinal disorders3/120/112/196/190/191/201/23
PyrexiaGeneral disorders0/120/112/191/191/191/207/23
AnaemiaBlood and lymphatic system disorders3/120/110/195/195/193/203/23
ThrombocytopeniaBlood and lymphatic system disorders2/120/110/193/194/195/204/23
DizzinessNervous system disorders3/120/110/190/190/191/201/23
NeutropeniaBlood and lymphatic system disorders1/120/112/194/193/193/205/23
Abdominal painGastrointestinal disorders1/120/112/194/191/191/203/23
ConstipationGastrointestinal disorders0/121/110/190/193/191/201/23
DiarrhoeaGastrointestinal disorders0/121/111/191/193/191/202/23

Baseline characteristics

For analysis purposes, baseline (BL) data are presented by study part groups. The BL analysis population includes all unique enrolled participants in Parts I, II, III, IV and V. Part III participants who entered Parts IV and V are only counted in Part III; Part IV participants who entered Part V are only counted in Part IV.

Age, Customized
Age, Customized(Participants)Part IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart V-fosaprepitant RegimenTotal
6 months to <2 years005661119
2 years to <6 years008860325
6 years to <12 years006674225
12 years to 17 years12110000023
Sex: Female, Male
Sex: Female, Male(Participants)Part IA-fosaprepitant 115 mg/AprepitantPart IB-fosaprepitant 150 mgPart IIA-aprepitant 80 mg Equiv.Part IIB-aprepitant 125 mg Equiv.Part III-ondansetronPart IV-aprepitant RegimenPart V-fosaprepitant RegimenTotal
Female771214133662
Male547662030
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kang HJ, Loftus S, Taylor A, DiCristina C, Green S, Zwaan CM. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):385-94. doi: 10.1016/S1470-2045(15)70061-6. Epub 2015 Mar 12. Erratum In: Lancet Oncol. 2015 Sep;16(9):e427. doi: 10.1016/S1470-2045(15)00237-5. PubMed 25770814 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2009 to primary completion in Jan 2014, 59 months.

Results were first posted in Nov 2014, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2009
First posted
Jan 7, 2009
StartActual
Feb 5, 2009
Primary completionActual
Jan 20, 2014
CompletionActual
Jan 20, 2014
Results first posted
Nov 18, 2014
Last update
Sep 25, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00818259
Responsible party
Sponsor
First posted
Jan 7, 2009
Start date
Feb 5, 2009
Primary completion
Jan 20, 2014
Completion
Jan 20, 2014
Results posted
Nov 18, 2014
Last update
Sep 25, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aprepitant · Fosaprepitant · Ondansetron

Start the discussion